143 related articles for article (PubMed ID: 35132704)
1. Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.
Meyer T; Caplin M; Khan MS; Toumpanakis C; Shetty S; Ramage JK; Houchard A; Higgs K; Shah T
J Neuroendocrinol; 2022 Apr; 34(4):e13096. PubMed ID: 35132704
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M; Ćwikła JB; Lombard-Bohas C; Borbath I; Shah T; Pape UF; Capdevila J; Panzuto F; Truong Thanh XM; Houchard A; Ruszniewski P
Eur J Cancer; 2021 Nov; 157():403-414. PubMed ID: 34597974
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
6. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
[TBL] [Abstract][Full Text] [Related]
7. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.
Rizzo FM; Vesely C; Childs A; Marafioti T; Khan MS; Mandair D; Cives M; Ensell L; Lowe H; Akarca AU; Luong T; Caplin M; Toumpanakis C; Krell D; Thirlwell C; Silvestris F; Hartley JA; Meyer T
Br J Cancer; 2019 Feb; 120(3):294-300. PubMed ID: 30636773
[TBL] [Abstract][Full Text] [Related]
9. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells and EpCAM expression in neuroendocrine tumors.
Khan MS; Tsigani T; Rashid M; Rabouhans JS; Yu D; Luong TV; Caplin M; Meyer T
Clin Cancer Res; 2011 Jan; 17(2):337-45. PubMed ID: 21224371
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Ferolla P; Berruti A; Spada F; Brizzi MP; Ibrahim T; Marconcini R; Giuffrida D; Amoroso V; La Salvia A; Vaccaro V; Faggiano A; Colao A; Volante M; Ghizzoni S; Mazzanti P; Houchard A; Fazio N
Neuroendocrinology; 2023; 113(3):332-342. PubMed ID: 36044870
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
16. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
Sun N; Yang Y; Miao H; Redublo P; Liu H; Liu W; Huang YW; Teng PC; Zhang C; Zhang RY; Smalley M; Yang P; Chou SJ; Huai K; Zhang Z; Lee YT; Wang JJ; Wang J; Liang IY; Zhang TX; Zhang D; Liang L; Weiss PS; Posadas EM; Donahue T; Hecht JR; Allen-Auerbach MS; Bergsland EK; Hope TA; Pei R; Zhu Y; Tseng HR; Heaney AP
Biosens Bioelectron; 2022 Mar; 199():113854. PubMed ID: 34896918
[TBL] [Abstract][Full Text] [Related]
18. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME; Pavel M; Phan AT; Ćwikła JB; Sedláčková E; Thanh XT; Wolin EM; Ruszniewski P;
Endocrine; 2021 Feb; 71(2):502-513. PubMed ID: 33052555
[TBL] [Abstract][Full Text] [Related]
19. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C; Phelip JM; Lievre A; Le-Malicot K; Dahan L; Tougeron D; Toumpanakis C; Di-Fiore F; Lombard-Bohas C; Borbath I; Coriat R; Lecomte T; Guimbaud R; Petorin C; Legoux JL; Michel P; Scoazec JY; Smith D; Walter T
Eur J Cancer; 2022 Nov; 175():31-40. PubMed ID: 36087395
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors.
Hsieh JC; Chen GY; Jhou DD; Chou WC; Yeh CN; Hwang TL; Lin HC; Chu HC; Wang HM; Yen TC; Chen JS; Wu MH
Sci Rep; 2019 Dec; 9(1):19917. PubMed ID: 31882775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]